(1 - 25 von 37
)
Brian P. Skorney | Benzinga
www.benzinga.com
Baird's Brian P. Skorney maintained a Neutral rating on the company, with a $268 price target. The stock appreciated following the announcement, since ...
Optimer Shares Rise After Report Names Glaxo, Cubist as Potential...
www.chemanager-online.com
Robert W. Baird & Co analyst Brian Skorney said the $1 billion target implied a price of about $18 per share, which, he felt, would be difficult to achieve. "I think we can see a $15 to $16 (per share) deal get done," Slorney said, calling the jump in Optimer's stock price a probable overreaction.
W. R. Berkley To Rally 25%? Here Are 5 Other Price Target ...
uk.investing.com
vor 5 Tagen — Baird analyst Brian Skorney maintained an Outperform rating on the stock. Albireo Pharma shares rose 0.4% to $ in pre-market trading. › news
Berlin: Von älteren Mäusen und Menschen - Tagesspiegel
www.tagesspiegel.de
— Ganz oben, im zehnten Stock des rostroten Backsteinturms, geht's nur noch im Schutzanzug weiter. „Keine Angst“, sagt Brian Skorney, 25, Biologe ... › berlin › von-alteren-mausen...
sortiert nach Relevanz / Datum